retatrutide type 2 diabetes trial results 2024 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a New Kind of Diabetes Drug

GLP-1 medications are physician-prescribed treatments that help regulate appetite, blood sugar, and metabolism

The study and a new Metabolic Psychiatry Hub highlight growing evidence that targeted ketosis may aid mood stabilization while improving metabolic health

NICE's existing frameworks for evaluating obesity pharmacotherapies including considerations of safety, efficacy, and cost-effectiveness will likely apply when retatrutide is formally assessed

Giugliano D, Scappaticcio L, Longo M, Bellastella G, Esposito K

Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: a post-market registry study

Retatrutide activates three receptors (GLP-1, GIP and glucagon), whereas Tirzepatide is a dual GLP-1 / GIP agonist